Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
复制标题

DOI:
10.1084/jem.20130590
复制
发表时间:
2014-04-07
期刊:
The Journal of experimental medicine
影响因子:
--
通讯作者:
Allison JP
Allison JP
中科院分区:
其他
文献类型:
--
作者:
Fan X;Quezada SA;Sepulveda MA;Sharma P;Allison JP

文献摘要

参考文献

被引文献

相似文献

CTLA-4阻断导致肿瘤反应性T细胞的活化增强,伴随着ICOS的上调,从而使它们的应答能够通过ICOS参与而增强。用单克隆抗体阻断细胞毒性T淋巴细胞抗原-4(CTLA-4)在一部分癌症患者中产生持久的反应,并已被FDA批准为晚期黑色素瘤的标准治疗。我们最近确定了诱导型共刺激分子(ICOS)作为CTLA-4阻断的抗肿瘤作用的关键参与者。我们现在表明,伴随的CTLA-4阻断和ICOS参与的肿瘤细胞疫苗工程表达ICOS配体增强抗肿瘤免疫应答的数量和质量,并显着改善排斥建立黑色素瘤和前列腺癌的小鼠。这项研究为开发结合抗CTLA-4和ICOS参与的组合疗法提供了强有力的支持。
CTLA-4 blockade leads to enhanced activation of tumor-reactive T cells with concomitant up-regulation of ICOS, thus enabling their responses to be enhanced by ICOS engagement. Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal antibody yields durable responses in a subset of cancer patients and has been approved by the FDA as a standard therapy for late-stage melanoma. We recently identified inducible co-stimulator (ICOS) as a crucial player in the antitumor effects of CTLA-4 blockade. We now show that concomitant CTLA-4 blockade and ICOS engagement by tumor cell vaccines engineered to express ICOS ligand enhanced antitumor immune responses in both quantity and quality and significantly improved rejection of established melanoma and prostate cancer in mice. This study provides strong support for the development of combinatorial therapies incorporating anti–CTLA-4 and ICOS engagement.
DOI: 10.1056/nejmoa1003466
发表时间: 2010-08-19
期刊: The New England journal of medicine
影响因子: --
作者:
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者: Urba WJ
DOI: 10.1084/jem.20130579
发表时间: 2013-08-26
期刊: The Journal of experimental medicine
影响因子: --
作者:
Simpson TR;Li F;Montalvo-Ortiz W;Sepulveda MA;Bergerhoff K;Arce F;Roddie C;Henry JY;Yagita H;Wolchok JD;Peggs KS;Ravetch JV;Allison JP;Quezada SA
通讯作者: Quezada SA
DOI: 10.1073/pnas.0806075105
发表时间: 2008-09-30
影响因子: 11.1
作者:
Liakou, Chrysoula I.;Kamat, Ashish;Sharma, Padmanee
通讯作者: Sharma, Padmanee
DOI: 10.1084/jem.194.9.1339
发表时间: 2001-11-05
影响因子: 15.3
作者:
Liu, XL;Bai, XF;Liu, Y
通讯作者: Liu, Y
DOI: 10.1126/scitranslmed.3000448
发表时间: 2010-10-27
影响因子: 17.1
作者:
Paulos CM;Carpenito C;Plesa G;Suhoski MM;Varela-Rohena A;Golovina TN;Carroll RG;Riley JL;June CH
通讯作者: June CH